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ICER of rituximab maintenance vs. observation alone is, there-
fore, estimated to be R$32,236 per QALY gained. The ICER of
rituximab maintenance was sensitive to the duration of treatment
beneﬁt, discount rate and drug cost. CONCLUSION: In patients
responding to induction therapy, rituximab maintenance therapy
improves overall survival and progression-free survival com-
pared with observation alone. Results suggest that maintenance
therapy with rituximab is a cost-effective intervention for the
management of patients with follicular lymphoma in the Brazil-
ian Private Healthcare System.
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OBJECTIVES: The goal of research was to investigate the cost
of DRG based anti-cancer chemotherapies. Costs for investi-
gated chemotherapies have been allocated to oncology centers
from the budget of National Heath Fund Administration, based
on DRG-reimbursement. METHODS: Cost analysis of chemo-
therapy protocols has been conducted, from the perspective of
National Heath Fund Administration, focusing on cost of medi-
cation, hospitalisation and the total expenditure of protocols.
RESULTS: The standard process of protocol-expenditure calcu-
lation has been identiﬁed. The drug related cost has been based
on the ex-factory prices of medicines. Expenditures of hospi-
talisation have been calculated on the days of total length of
drug administration and not on term of hospitalisation. Che-
motherapies, containing per os anti-cancer medication have
been found over-charged. The cost ratio of oral drug and pro-
tocol expenses has been found lower than the average of oncol-
ogy protocols, from 1,75 to 26.9%. Consequetly, the cost of
hospitalisaton has been over-represented in these protocolls,
although these treatments have reqired less hospitalisation.
Using per os chemotherapy protocols has resulted idle capacity
in utilization of protocol-expenditures. CONCLUSION: The
cost of hospitalisation based on “days of treatment” hasn’t
reﬂected correctly the occurrent expenses. Per os chemothera-
pies alone should have been reimbursed as outpatient care and
not involved into DRG based hospital care. The cost of proto-
cols, containing per os and i.v. compounds in combination
should have been calculated on a real-cost basis, considering
the days of hospitalisation.
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OBJECTIVES: To calculate the burden of cancer in the private
and public healthc care sector, compare it to the health care
resources consumed, and to other disease areas. Ultimately we
seek to understand whether scarce health care resource allocation
is optimally distributed between different diseases. METHODS:
We ﬁrst attempted to calculate the burden of cancer for South
Africa using Statistics SA, South African death registry and the
National Cancer Registry data. Using different data sets we then
differentiated the data in order to estimate the public and private
sector burden of cancer. By using the latest South African
National Health Accounts and medical insurance data, we then
calculated the direct monetary health care resources for cancer
and other diseases. Lastly we attempted to calculate the indirect
costs associated with cancer and other diseases using the human
capital methodology. We were able to compare burden of cancer,
cardiovascular disease, diabetes, HIV/AIDS, injuries, mental
disease, respiratory disease and all other diseases to the direct
monetary health care resources as well as the indirect costs
associated with disease. RESULTS: HIV/AIDS and injuries con-
tributed 30.9% and 14.3% to the burden of disease in South
Africa while cancer was 3.1%. When comparing the direct health
care cost as a percentage of total health care spending to the
cancer DALY as a percentage of total DALY, the ratio was 1.07.
This indicates that, from a direct health care cost perspective,
direct health care cost consumption was proportionate to the
burden. However, when comparing direct health care cost per-
centage to indirect costs percentage, the ratio for cancer is 0.36.
Similar results were seen in the public and private sector. CON-
CLUSION: From a societal perspective, it appears that too little
resources are allocated to cancer and some other chronic diseases
in South Africa.
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OBJECTIVES: The aim of this study is to compare the distri-
bution of health insurance treatment cost of and mortality due
to cervical cancer according to age-groups. METHODS: Data
derive from the database of the National Health Insurance Fund
Administration (OEP) containing routinely collected ﬁnancial
data. The study includes all the women who received outpatient
and/or inpatient care treatment in 2001 ﬁnanced from public
resources of OEP. Number of deaths due to cervical cancer is
from the Central Statistical Ofﬁce database. We compared the
annual out- and inpatient care treatment cost and the annual
number of deaths according to age groups. RESULTS: The cost
distribution of out- and inpatient care treatment cost of cervical
cancer was the following (outp./inp.): 0–24 years: 0.2%/0.2%;
25–44 years: 33.2%/35.8%; 45–64 years: 47.2%/47.3%; 65–74
years: 12.9%/13.2%; 75 and over: 6.5%/3.6%. The distribu-
tion of deaths due to cervical cancer was the following: 0–24
years: 0.0%; 25–44 years: 16.3%; 45–64 years: 41.0%; 65–74
years: 21.7%; 75 and over: 21.0%. Summarizing these
numbers, women aged 0–64 years accounts for 57.3% of all
deaths due to cervical cancer but they received 80.6% and
83.3% of treatment cost of in- and outpatient care. While
women aged 65 or over accounts for 42.7% of deaths and
consumed only 19.4% and 16.7% of of treatment cost of in-
and outpatient care. CONCLUSION: Women in younger age
groups received more treatment cost than its mortality would
predict, while women in older age groups received less treat-
ment cost of out- and inpatient care. There is a shift between
the distribution of treatment cost of and deaths due to cervical
cancer in favor of younger age-groups.
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